

## RECEIVED

**TECH CENTER 1600/2900** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

J. Kevin Judice et al.

Title:

PHARMACEUTICAL COMPOSITIONS CONTAINING A GLYCOPEPTIDE ANTIBIOTIC AND A

**CYCLODEXTRIN** 

Docket No.:

1343.016US1

Filed:

May 1, 2001

Examiner:

Unknown

Serial No.: 09/846,893

Due Date: N/A

Group Art Unit: 1614

Commissioner for Patents Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

A return postcard.

 $\frac{\mathbf{X}}{\mathbf{X}}$ A Supplemental Information Disclosure Statement (1 pg.), Form 1449 (1 pg.), and copy of 1 cited reference.

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

Atty: Robert J. Harris, Ph.D.

Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 26 day of February, 2002.

Alisia G. Dunbar

Name

**Customer Number 21186** 

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

(GENERAL)

S/N 09/846,893

<u>PATENT</u>
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

6 ZOUL E

J. Kevin Judice et al.

Examiner: Unknown

Applicant:

J. Kevili Judice et al

Examiner. Officiowii

Serial No.:

09/846,893

Group Art Unit: 1614

Filed:

May 1, 2001

Docket: 1343.016US1

Title:

PHARMACEUTICAL COMPOSITIONS CONTAINING A GLYCOPEPTIDE

ANTIBIOTIC AND A CYCLODEXTRIN

INING A GLYCOPEPTIDE

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants further request that a copy of the 1449 form, initialed by the Examiner to indicate that all listed citations have been considered, be returned with the next official communication.

Under 37 C.F.R. §1.97(b)(3), it is believed that no fee or certificate is required with this Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Account No. 19-0743.

The Examiner is invited to contact the Applicants' Representatives at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

J. KEVIN JUDICE ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 359-3265

Date 2 -25-02

Robert J. Harris, Ph.D. Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this day of February, 2002.

Alisia G. Dunbar

Signature MRM

Name